Document Detail

Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG.
MedLine Citation:
PMID:  16869794     Owner:  NLM     Status:  MEDLINE    
Here we retrospectively examine the efficacy of two antibody induction regimens using Zenapax or Thymoglobulin in patients with positive complement-dependent cytotoxicity crossmatches (CDC-CMXs) desensitized with IVIG (intravenous immunoglobulin). Between January 1999 and March 2005, 97 patients with (+) CDC-CMXs received kidney transplants (43 deceased donors/54 living donors). All patients received at least 2 g/kg IVIG (maximum four doses) until an acceptable CMX was obtained. Patients were divided into two groups: 1. IVIG + Zenapax (n = 58), 2. IVIG + Thymoglobulin (n = 39). A total of 94% of patients in Group 1 and 84% in G2 have at least 2 years of follow up. Patient and graft survival was 96%/84% in Group 1 and 100%/90% in Group 2, p = NS. The number and severity of AR episodes were similar (36% Group 1 vs. 31% Group 2, p = NS) as was the incidence of C4d (+) antibody-mediated rejection (AMR) (Banff Grade II/III) (22% Group 1 vs. 21% Group 2). Mean serum creatinines (SCrs) at 24 months were similar (Group 1: 1.4 +/- 0.7 vs. G2: 1.5 +/- 0.7 mg/dL). Induction therapy with Zenapax or Thymoglobulin results in excellent patient, graft survival and graft function at 2 years. There was no increased risk of viral infections or malignancies with either agent. Neither agent was effective in reducing the incidence of AMR.
A A Vo; M Toyoda; A Peng; S Bunnapradist; M Lukovsky; S C Jordan
Related Documents :
629874 - Treatment of eczema with cyclophosphamide and azathioprine.
11593244 - Effect of methyl prednisolone on sensory motor functions in tuberculous meningitis.
15477504 - Intravenous immunoglobulin treatment following the first demyelinating event suggestive...
3460404 - Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid ther...
15502574 - Analysis of scar formation after lower limb lengthening: influence on cosmesis and pati...
2870314 - Cerebral consequences of cardiopulmonary bypass.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-07-25
Journal Detail:
Title:  American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons     Volume:  6     ISSN:  1600-6135     ISO Abbreviation:  Am. J. Transplant.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-14     Completed Date:  2006-12-19     Revised Date:  2007-02-14    
Medline Journal Info:
Nlm Unique ID:  100968638     Medline TA:  Am J Transplant     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  2384-90     Citation Subset:  IM    
Comprehensive Transplant Center, Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Antibodies, Monoclonal / therapeutic use*
Child, Preschool
Drug Therapy, Combination
Follow-Up Studies
Graft Rejection / immunology,  prevention & control*
Graft Survival
Histocompatibility Testing
Immunoglobulin G / therapeutic use*
Immunoglobulins, Intravenous / therapeutic use*
Immunologic Factors / therapeutic use*
Immunosuppression / methods
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*
Middle Aged
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Immunosuppressive Agents; 0/thymoglobulin; 152923-56-3/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The beginning of the end of frustration.
Next Document:  Renal allograft injury is associated with urinary tract infection caused by Escherichia coli bearing...